MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/16078454.2025.2532893

Медицинская библиотека · Hematology (Amsterdam, Netherlands) · 2025

Meta-analysis of the prognostic efficacy of daratumumab combined with standard therapy in high-risk multiple myeloma.

Zhou Hongmei, Zhang Min, Jin Yi, Lang Xianghua

СтатьяМетаанализПеревод пока не подготовлен

Аннотация

OBJECTIVE

This meta-analysis aims to evaluate the efficacy of daratumumab (DAR) in combination with standard therapy for the treatment of high-risk multiple myeloma (HRMM), offering evidence-based insights to guide clinical decision-making.

METHODS

A comprehensive search was conducted across literature databases to identify studies investigating the use of DAR in HRMM. After removing duplicates, titles, abstracts, and full texts were screened. Study quality was assessed using the Cochrane Handbook for Systematic Reviews of Interventions (version 5.1.0). Studies with high risk of bias were excluded. Data on authors, publication dates, study populations, objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse events were analyzed using RevMan 5.3 software.

RESULTS

11 studies were included, comprising 2330 patients in the control group (standard therapy) and 2663 patients in the experimental group (DAR plus standard therapy). All studies were rated as having a low to moderate risk of bias. Meta-analysis showed that ORR, PFS, and OS were significantly higher in the experimental group (P < 0.05). The incidence of anemia was lower in the DAR group, while thrombocytopenia and neutropenia were more frequent (P < 0.05). Funnel plot analysis suggested minimal publication bias.

CONCLUSION

The combination of DAR with standard therapy significantly enhances clinical outcomes in HRMM patients, resulting in prolonged PFS and OS, with manageable adverse effects.

Для цитирования: Zhou Hongmei, Zhang Min, Jin Yi, Lang Xianghua. Meta-analysis of the prognostic efficacy of daratumumab combined with standard therapy in high-risk multiple myeloma.. Hematology (Amsterdam, Netherlands). 2025. DOI: 10.1080/16078454.2025.2532893.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.